表紙
市場調査レポート

MediGene AG : 製品パイプライン分析

MediGene AG - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224623
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
MediGene AG : 製品パイプライン分析 MediGene AG - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 42 Pages
概要

MediGene AGは、癌や自己免疫疾患治療用の新薬の臨床研究、開発、販売を行っているバイオテクノロジー企業です。

当レポートでは、MediGene AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

MediGene AGの基本情報

MediGene AGの概要

  • 主要情報
  • 企業情報

MediGene AG:R&Dの概要

  • 主な治療範囲

MediGene AG:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

MediGene AG:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

MediGene AG:薬剤プロファイル

  • sinecatechins
  • 前立腺癌の細胞療法
  • RhuDex
  • 急性骨髄性白血病(AML)の細胞療法2
  • 急性骨髄性白血病(AML)の細胞療法
  • G-207
  • 腫瘍の FMNL1 標的細胞療法
  • ヒト・パピローマウイルス 血清型 16, 31用 ウイルス様粒子ワクチン
  • 白血病および自己免疫疾患治療のための抗TCRモノクローナル抗体

MediGene AG:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

MediGene AG:最近のパイプライン動向

MediGene AG:休止中のプロジェクト

MediGene AG:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • L1 モノクローナル抗体

MediGene AG:企業発表

MediGene AG:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07370CDB

Summary

Global Markets Direct's, 'MediGene AG - Product Pipeline Review - 2015', provides an overview of the MediGene AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MediGene AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of MediGene AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MediGene AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MediGene AG's pipeline products

Reasons to buy

  • Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MediGene AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MediGene AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MediGene AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MediGene AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MediGene AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MediGene AG Snapshot
    • MediGene AG Overview
    • Key Information
    • Key Facts
  • MediGene AG - Research and Development Overview
    • Key Therapeutic Areas
  • MediGene AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • MediGene AG - Pipeline Products Glance
    • MediGene AG - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • MediGene AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • MediGene AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • MediGene AG - Drug Profiles
    • sinecatechins
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RhuDex
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy 2 for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-207
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target FMNL1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus [serotypes 16, 31] virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MediGene AG - Pipeline Analysis
    • MediGene AG - Pipeline Products by Target
    • MediGene AG - Pipeline Products by Route of Administration
    • MediGene AG - Pipeline Products by Molecule Type
    • MediGene AG - Pipeline Products by Mechanism of Action
  • MediGene AG - Recent Pipeline Updates
  • MediGene AG - Dormant Projects
  • MediGene AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • L1 Monoclonal Antibody
  • MediGene AG - Company Statement
  • MediGene AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MediGene AG, Key Information
  • MediGene AG, Key Facts
  • MediGene AG - Pipeline by Indication, 2015
  • MediGene AG - Pipeline by Stage of Development, 2015
  • MediGene AG - Monotherapy Products in Pipeline, 2015
  • MediGene AG - Out-Licensed Products in Pipeline, 2015
  • MediGene AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • MediGene AG - Pre-Registration, 2015
  • MediGene AG - Phase II, 2015
  • MediGene AG - Phase I, 2015
  • MediGene AG - Preclinical, 2015
  • MediGene AG - Discovery, 2015
  • MediGene AG - Pipeline by Target, 2015
  • MediGene AG - Pipeline by Route of Administration, 2015
  • MediGene AG - Pipeline by Molecule Type, 2015
  • MediGene AG - Pipeline Products by Mechanism of Action, 2015
  • MediGene AG - Recent Pipeline Updates, 2015
  • MediGene AG - Dormant Developmental Projects,2015
  • MediGene AG - Discontinued Pipeline Products, 2015
  • MediGene AG, Subsidiaries

List of Figures

  • MediGene AG - Pipeline by Top 10 Indication, 2015
  • MediGene AG - Pipeline by Stage of Development, 2015
  • MediGene AG - Monotherapy Products in Pipeline, 2015
  • MediGene AG - Out-Licensed Products in Pipeline, 2015
  • MediGene AG - Pipeline by Top 10 Target, 2015
  • MediGene AG - Pipeline by Top 10 Route of Administration, 2015
  • MediGene AG - Pipeline by Top 10 Molecule Type, 2015
  • MediGene AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top